Chorus

EQS-News: TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients

Retrieved on: 
Monday, February 13, 2023
USD, Allergic rhinitis, Asthma, PFC, Adrenaline, Mab, Human, Life, Death, CFO, Health, Allergy, LSI, CMO, Eli Lilly and Company, General partnership, Food allergy, Immunoglobulin E, TVM, Quality of life, Patient, Risk, Food, Investment, Vaccine, Pharmaceutical industry, Chorus, Lilly

LAmAb Biologics to develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases

Key Points: 
  • LAmAb Biologics to develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases
    Montreal, Canada / Munich, Germany – 08 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will invest up to USD 25 million in the newly formed U.S.-based biotechnology company, LAmAb Biologics (“LAmAb”), with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”).
  • LAmAb is the 9th early-stage or project-focused company (PFC) investment for TVM LS II.
  • "TVM Capital Life Science is proud to have enabled the creation of LAmAb Biologics and to have secured the rights to a novel first-in-class asset with the potential to positively impact challenging-to-treat allergic diseases.
  • Better options are urgently needed to provide patients, especially those suffering from multiple allergies, with more effective and safer therapeutic options.

TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients

Retrieved on: 
Wednesday, February 8, 2023
Health, Mab, CMO, Allergy, Human, Asthma, Life, General partnership, LSI, Quality of life, TVM, Risk, Death, Food, Eli Lilly and Company, Food allergy, Immunoglobulin E, Allergic rhinitis, Patient, Adrenaline, Investment, PFC, USD, CFO, Vaccine, Pharmaceutical industry, Lilly, Chorus

MONTREAL and MUNICH, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will invest up to USD 25 million in the newly formed U.S.-based biotechnology company, LAmAb Biologics (“LAmAb”), with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”). TVM will provide strategic advice to the company, with Dr. Sascha Berger, General Partner joining the Board of Directors and Marc Rivière, M.D., CMO, serving as a Board Observer. LAmAb is the 9th early-stage or project-focused company (PFC) investment for TVM LS II.

Key Points: 
  • LAmAb is the 9th early-stage or project-focused company (PFC) investment for TVM LS II.
  • LAmAb plans to develop a first-in-class monoclonal antibody (mAb) to clinical proof-of-concept in allergic rhinitis (hay fever), an indication that should enable LAmAb to efficiently show the program may be effective in humans.
  • “TVM Capital Life Science is proud to have enabled the creation of LAmAb Biologics and to have secured the rights to a novel first-in-class asset with the potential to positively impact challenging-to-treat allergic diseases.
  • This investment is a testament to our strong international network and builds on our successful single asset focus for innovative preclinical therapeutic agents,” said Sascha Berger, General Partner of TVM Capital Life Science and Member of the Board of LAmAb Biologics.

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Retrieved on: 
Wednesday, February 1, 2023
Standard of care, Breast, Partner (business rank), NCE, Cancer, LSI, TVM, B cell, Eli Lilly and Company, Taxane, Neoplasm, Ovary, Prostate, Investment, Recurrence, Cell, PFC, USD, Associate, Medical imaging, Pharmaceutical industry, Lilly, Recurve bow, Chorus

MONTREAL and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced that the company will invest up to USD 24 million in the newly formed U.S.-based biotechnology company, Recurv Pharma, Inc. (“Recurv”) with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”). Recurv plans to develop to proof-of-concept a novel taxane therapy to treat solid tumors. Also, TVM will provide strategic advice to the company with Dr. Luc Marengère, Managing Partner joining the Board of Directors and Dr. Valentina Agostoni, Associate, serving as a Board Observer.   Recurv is the 8th early-stage or project-focused company (PFC) investment for the TVM Life Science Innovation II Fund.

Key Points: 
  • Recurv plans to develop to proof-of-concept a novel taxane therapy to treat solid tumors.
  • Also, TVM will provide strategic advice to the company with Dr. Luc Marengère, Managing Partner joining the Board of Directors and Dr. Valentina Agostoni, Associate, serving as a Board Observer.
  • Recurv is the 8th early-stage or project-focused company (PFC) investment for the TVM Life Science Innovation II Fund.
  • James E. Egan, CEO of Recurv, said: “TVM’s investment is designed to get us to a key value inflection point, namely, Phase 2a proof-of-concept, with our cancer program, RP-001.

The National Children's Chorus (NCC) Launches Opera Division and New VAIL OPERA CAMP Initiative Under the Leadership of Artistic Director Luke McEndarfer

Retrieved on: 
Wednesday, January 25, 2023
Education, McCullough, Brothers Grimm, Los Angeles Opera, Performing arts, Chorus, Student, The Brave Little Tailor, QR, The Barber of Seville, NCC, Music, Singing, Faculty, Merola Opera Program, National Children's Chorus, Enrollment, Rocky Mountains, Grimm Fairy Tales (comics), Tinker, Entertainment

NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The GRAMMY® Award-winning National Children's Chorus is teaming up with its newly appointed Opera Program Director, GRAMMY®-nominated Johnathan McCullough, to launch the organization's new VAIL OPERA CAMP initiative and Opera Vocal Studies program.

Key Points: 
  • NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The GRAMMY® Award-winning National Children's Chorus is teaming up with its newly appointed Opera Program Director, GRAMMY®-nominated Johnathan McCullough, to launch the organization's new VAIL OPERA CAMP initiative and Opera Vocal Studies program.
  • This August, all participants will convene in Vail, Colorado, to mount a fully staged opera and learn opera history, stagecraft, design, and acting.
  • For more information about VAIL OPERA CAMP and to set up an audition, please visit https://nationalchildrenschorus.com/opera-camp/ or scan the QR code ( https://imgur.com/a/RjFsVt8 ).
  • He is a distinguished NCC alumnus and looks forward to rejoining the organization — this time as a Program Director," said Luke McEndarfer, Artistic Director and CEO.

Jazz Aviation celebrates 12 years as Top Employer in Atlantic Canada and Nova Scotia

Retrieved on: 
Thursday, January 19, 2023
Health, Aviation, Jazz (airline), NS, TSX, Canada, Chorus, Jazz, CHR, Health insurance, Atlantic Canada

HALIFAX, NS, Jan. 19, 2023 /CNW/ - Chorus Aviation Inc. ('Chorus') (TSX: CHR) is proud to announce that subsidiary Jazz Aviation LP ('Jazz') is named a Top Employer in Atlantic Canada and Nova Scotia by Mediacorp Canada Inc. for the twelfth consecutive year.

Key Points: 
  • HALIFAX, NS, Jan. 19, 2023 /CNW/ - Chorus Aviation Inc. ('Chorus') (TSX: CHR) is proud to announce that subsidiary Jazz Aviation LP ('Jazz') is named a Top Employer in Atlantic Canada and Nova Scotia by Mediacorp Canada Inc. for the twelfth consecutive year.
  • "We're proud of our long history in this region and being an employer of choice for Nova Scotians and Atlantic Canadians," said Randolph deGooyer, President, Jazz.
  • "We're very honoured to be recognized for providing a safe and inclusive work environment where employees have the tools they need to succeed."
  • These special designations recognize employers in Nova Scotia and Atlantic Canada that lead their industries in offering exceptional places to work.

Ocean House Celebrates and Supports the Performing Arts with the Return of an Annual Gala in Watch Hill, Rhode Island

Retrieved on: 
Tuesday, January 17, 2023
Music, Music school, High Street, Black, Chorus of Westerly, Student, Black and White Ball, Rhode Island Philharmonic Orchestra, Education, Ocean, Creativity, Season, Culture, Philippines Charitable Giving Assistance Act, The Magic Flute, Wine, Collection, Anglo-French Wars, Organization, Food, The arts, Veuve Clicquot, Travel + Leisure, Salt Marsh Opera, Sampford Arundel, Forbes Travel Guide, Entertainment, Nightclub, Hotel, Westerly, Atlantic Ocean, Chorus

WATCH HILL, R.I., Jan. 17, 2023 /PRNewswire/ -- Ocean House, the Forbes triple Five-Star destination hotel nestled on the bluffs of scenic Watch Hill, Rhode Island, today announced it will bring back its esteemed Black & White Ball in 2023 in celebration and support of performing arts.

Key Points: 
  • Proceeds of the event will benefit three locally based performing arts organizations including the UNITED Theatre, the Chorus of Westerly and Salt Marsh Opera.
  • This year's Black & White Ball United for the Arts will be underwritten by sponsors including Ocean House and the Ocean House Fund for Charitable Giving.
  • The UNITED is a non-profit regional center for arts and arts education showcasing world-class performing, visual and creative work.
  • Originally built just after the Civil War, Ocean House is perched high on the bluffs in the charming seaside Watch Hill village.

New Zealand Data Center Market Report 2022: Investment Analysis & Growth Opportunities 2021-2027 - Market to Grow by $1.2 Billion

Retrieved on: 
Thursday, January 12, 2023
Cloud, Big data, Spark New Zealand, Data vault, Auckland Transport, AZS, Wind, Government, IOT, Internet of things, AI, Cloud computing, Greenhouse, Artificial intelligence, ICT, Investment, Microsoft, Computer network, RESEARCH, AWS, Software as a service, USD, Electricity, Renewable energy, Retail, Internet service provider, Chorus, Vodafone

DUBLIN, Jan. 12, 2023 /PRNewswire/ -- The "New Zealand Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 12, 2023 /PRNewswire/ -- The "New Zealand Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • This report analyses the New Zealand data center market share.
  • Market size available in the investment, area, power capacity, and the New Zealand colocation market revenue.
  • During the forecast period, a detailed study of the existing market landscape, an in-depth industry analysis, and insightful predictions about the New Zealand data center market size.

EQS-News: TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Retrieved on: 
Thursday, February 2, 2023
Partner (business rank), Cell, Associate, Prostate, Cancer, Ovary, B cell, Standard of care, PFC, Eli Lilly and Company, Breast, LSI, Neoplasm, TVM, NCE, Recurrence, Taxane, USD, Investment, Fine chemical, Medical imaging, Pharmaceutical industry, Lilly, Chorus, Recurve bow

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Key Points: 
  • TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.
  • TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc
    Recurv is developing novel taxane, RP-001, against solid tumors
    RP-001 delivered in nano-emulsion formulation, focusing drug delivery to tumor and sparing healthy organs
    Strong efficacy in multiple pre-clinical cancer models, including multi-drug resistant tumors
    Montreal, Canada / Munich, Germany – 01 February 2023 – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced that the company will invest up to USD 24 million in the newly formed U.S.-based biotechnology company, Recurv Pharma, Inc. (“Recurv”) with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”).
  • Recurv plans to develop to proof-of-concept a novel taxane therapy to treat solid tumors.
  • Recurv is the 8th early-stage or project-focused company (PFC) investment for the TVM Life Science Innovation II Fund.

New Zealand Data Center Market Investment Analysis & Growth Opportunities Report 2022-2027 Featuring Key Investors - Datacom, Data Vault, Microsoft, Plan B, & Spark Digital - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Technology, Hardware, Data Management, Cloud, Big data, Spark New Zealand, Data vault, Auckland Transport, AZS, Wind, Government, IOT, Internet of things, AI, Cloud computing, Greenhouse, Artificial intelligence, ICT, Investment, Microsoft, Computer network, RESEARCH, AWS, Software as a service, USD, Electricity, Renewable energy, Retail, Internet service provider, Chorus, Vodafone

The "New Zealand Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "New Zealand Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • This report analyses the New Zealand data center market share.
  • Market size available in the investment, area, power capacity, and the New Zealand colocation market revenue.
  • During the forecast period, a detailed study of the existing market landscape, an in-depth industry analysis, and insightful predictions about the New Zealand data center market size.

Advisory - Chorus Aviation Inc. to Present Fourth Quarter and Year-End 2022 Financial Results on February 16, 2023

Retrieved on: 
Tuesday, January 10, 2023
TSX, CHR, Chorus, Aviation, Telephone, Management, NS

HALIFAX, NS, Jan. 10, 2023 /CNW/ - Chorus Aviation Inc. ("Chorus") (TSX: CHR) will present the company's fourth quarter and year-end 2022 financial results on Thursday, February 16, 2023.

Key Points: 
  • HALIFAX, NS, Jan. 10, 2023 /CNW/ - Chorus Aviation Inc. ("Chorus") (TSX: CHR) will present the company's fourth quarter and year-end 2022 financial results on Thursday, February 16, 2023.
  • Joe Randell, President and Chief Executive Officer, Colin Copp, Chief Operating Officer and President, Chorus Aviation Services, and Gary Osborne, Chief Financial Officer, will present fourth quarter and year-end results and will be available for analysts' questions.
  • Media may access this call on a listen-in basis.
  • Please allow 10 minutes to be connected to the conference call.